Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15 year follow up of a phase II study from MD Anderson Cancer Center

BACKGROUND: Mantle cell lymphoma remains an aggressive and incurable malignancy. Intensive chemotherapy regimens containing cytarabine have substantially improved remission durability and overall survival, particularly in younger adults. However, there have been no long-term follow-up results for pa...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Br J Haematol
Autori principali: Chihara, Dai, Cheah, Chan Yoon, Westin, Jason R., Fayad, Luis E., Rodriguez, Maria Alma, Hagemeister, Fredrick B., Pro, Barbara, McLaughlin, Peter, Younes, Anas, Samaniego, Felipe, Goy, Andre, Cabanillas, Fernando, Kantarjian, Hagop, Kwak, Larry W., Wang, Michael L., Romaguera, Jorge E.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2015
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5471614/
https://ncbi.nlm.nih.gov/pubmed/26648336
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.13796
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi